PL2649068T3 - Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX - Google Patents

Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX

Info

Publication number
PL2649068T3
PL2649068T3 PL11804810T PL11804810T PL2649068T3 PL 2649068 T3 PL2649068 T3 PL 2649068T3 PL 11804810 T PL11804810 T PL 11804810T PL 11804810 T PL11804810 T PL 11804810T PL 2649068 T3 PL2649068 T3 PL 2649068T3
Authority
PL
Poland
Prior art keywords
oxazolyl
receptor agonists
alx receptor
methylether derivatives
methylether
Prior art date
Application number
PL11804810T
Other languages
English (en)
Inventor
Daniel Bur
Olivier Corminboeuf
Sylvaine Cren
Corinna Grisostomi
Xavier Leroy
Sylvia Richard-Bildstein
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of PL2649068T3 publication Critical patent/PL2649068T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL11804810T 2010-12-07 2011-12-06 Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX PL2649068T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2010055616 2010-12-07
EP11804810.7A EP2649068B1 (en) 2010-12-07 2011-12-06 Oxazolyl-methylether derivatives as alx receptor agonists
PCT/IB2011/055487 WO2012077049A1 (en) 2010-12-07 2011-12-06 Oxazolyl-methylether derivatives as alx receptor agonists

Publications (1)

Publication Number Publication Date
PL2649068T3 true PL2649068T3 (pl) 2015-03-31

Family

ID=45444667

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11804810T PL2649068T3 (pl) 2010-12-07 2011-12-06 Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX

Country Status (19)

Country Link
US (1) US8846733B2 (pl)
EP (1) EP2649068B1 (pl)
JP (1) JP5923107B2 (pl)
KR (1) KR101864463B1 (pl)
CN (1) CN103261194B (pl)
AR (1) AR084173A1 (pl)
AU (1) AU2011340146B2 (pl)
CA (1) CA2816376C (pl)
CY (1) CY1116004T1 (pl)
DK (1) DK2649068T3 (pl)
ES (1) ES2526132T3 (pl)
HR (1) HRP20150049T1 (pl)
MX (1) MX2013006418A (pl)
PL (1) PL2649068T3 (pl)
PT (1) PT2649068E (pl)
RU (1) RU2588567C2 (pl)
SI (1) SI2649068T1 (pl)
TW (1) TWI523853B (pl)
WO (1) WO2012077049A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012066488A2 (en) 2010-11-17 2012-05-24 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
WO2013171687A1 (en) 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
TW201536289A (zh) 2013-07-18 2015-10-01 Actelion Pharmaceuticals Ltd 作為ａｌｘ受體激動劑之經哌取代橋聯螺［２，４］庚烷衍生物
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
NZ720508A (en) 2013-11-28 2019-03-29 Kyorin Seiyaku Kk Urea derivative or pharmacologically acceptable salt thereof
EP3303284B1 (en) 2015-05-27 2020-04-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
EA201792382A1 (ru) 2015-05-27 2018-04-30 Киорин Фармасютикал Ко., Лтд. Производное мочевины или его фармакологически приемлемая соль
US11439615B2 (en) 2017-03-09 2022-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
AU2019232704B2 (en) 2018-03-05 2024-03-21 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
KR20030030029A (ko) 2000-09-22 2003-04-16 니혼노야쿠가부시키가이샤 Ｎ-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법
AU2003214249A1 (en) 2002-04-03 2003-10-13 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
KR20060130064A (ko) 2003-11-07 2006-12-18 아카디아 파마슈티칼스 인코포레이티드 통증 및 염증 치료에 효과적인 화합물을 동정하기 위한도구로서의 리폭신 수용체, ｆｐｒｌ1의 용도
US7323480B2 (en) * 2004-05-25 2008-01-29 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
WO2007055941A2 (en) 2005-11-03 2007-05-18 Merck & Co., Inc. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
RU2522456C2 (ru) 2007-08-21 2014-07-10 Синомикс, Инк. Соединения, ингибирующие (блокирующие) горький вкус, способы их применения и получения
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
MX2010006241A (es) 2007-12-18 2010-06-30 Actelion Pharmaceuticals Ltd Derivados de aminotriazol como agonistas de alx.
NZ597122A (en) 2009-05-18 2013-06-28 Actelion Pharmaceuticals Ltd Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists
CN101909306A (zh) * 2009-06-08 2010-12-08 中兴通讯股份有限公司 中继站管理方法及基站
WO2010143116A1 (en) 2009-06-09 2010-12-16 Actelion Pharmaceuticals Ltd Fluorinated aminotriazole derivatives
KR20120046159A (ko) 2009-06-12 2012-05-09 액테리온 파마슈티칼 리미티드 Ａｌｘ 수용체 아고니스트로서의 옥사졸 및 티아졸 유도체
JP2012254939A (ja) * 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物

Also Published As

Publication number Publication date
HRP20150049T1 (hr) 2015-02-27
CN103261194B (zh) 2016-02-24
US8846733B2 (en) 2014-09-30
CY1116004T1 (el) 2017-01-25
JP5923107B2 (ja) 2016-05-24
TWI523853B (zh) 2016-03-01
CA2816376C (en) 2018-11-20
MX2013006418A (es) 2013-07-15
EP2649068A1 (en) 2013-10-16
CA2816376A1 (en) 2012-06-14
RU2013130879A (ru) 2015-01-20
WO2012077049A1 (en) 2012-06-14
KR101864463B1 (ko) 2018-06-04
EP2649068B1 (en) 2014-10-29
TW201305151A (zh) 2013-02-01
CN103261194A (zh) 2013-08-21
PT2649068E (pt) 2014-12-23
ES2526132T3 (es) 2015-01-07
AU2011340146B2 (en) 2016-05-19
AR084173A1 (es) 2013-04-24
AU2011340146A1 (en) 2013-07-25
RU2588567C2 (ru) 2016-07-10
DK2649068T3 (en) 2014-12-08
KR20130133240A (ko) 2013-12-06
SI2649068T1 (sl) 2015-01-30
US20130261159A1 (en) 2013-10-03
JP2013544878A (ja) 2013-12-19

Similar Documents

Publication Publication Date Title
PL2649068T3 (pl) Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX
IL222646A0 (en) N3-substituted -n1-sulfonyl-5-fluoropyrimidinone derivatives
ZA201208447B (en) Indoles
EP2646020A4 (en) INDOLES
ZA201209117B (en) Tetrahydro-pyrido-pyrimidine derivatives
GB201410398D0 (en) Muscarinic m1 receptor agonists
IL229320A0 (en) History of 3-spirocyclic piperidines as ghrelin receptor agonists
EP2569324A4 (en) Aminoglycoside DERIVATIVES
GB2490849B (en) Di-aspirin derivatives
EP2566494A4 (en) CXCR4 RECEPTOR COMPOUNDS
HU1000243D0 (en) 8-hidroxy-quinoline derivatives
IL225393A0 (en) History of Indole
GB201116152D0 (en) Cannabinoid-2-receptor agonists
GB2485874B (en) Beam hanger
TWM387187U (en) Monitor hanging structure
GB201116151D0 (en) Cannabinoid-2-receptor agonists
ZA201209248B (en) Amido-tropane derivatives
IL220983A0 (en) 2-aldoximino-5-fluoropyrimidine derivatives
GB201004821D0 (en) Cylinder pivoting device
HK1186116A (en) Microcrystalline y receptor agonists
TWM402665U (en) Improved structure for hanger
TWM385717U (en) Monitor adjustment structure